Until now, clinicians have been challenged to improve the treatment of biochemically
recurrent (BCR) prostate cancer in which prostatic specific antigen (PSA) rises without
radiological or clinical progression years after localized treatment (radical prostatectomy
or radiation therapy) with or without hormonal treatment. Approximately 50-90% of men with
high-risk prostate cancer will experience a BCR. Artesunate has demonstrated anti-tumor
activity in both in vivo and in vitro cell lines. It is hypothesized that Artemisia annua
(Aa) coffee has the potential to decrease rising PSA among patients with biochemical
recurrence of prostate cancer.